SYMPOSIA
SYMPOSIA
SYMPOSIA
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Bulletin of Clinical Psychopharmacology, Vol: 21, Supplement: 2, 2011 - www.psikofarmakoloji.org<br />
Abstracts of the Invited Speakers<br />
Psychiatric Association), several treatment approaches received strong endorsement for BN. Cognitive behavioral therapy (CBT) is<br />
recommended as an effective treatment for bulimic patients and considered the ‘treatment choice’ for BN and binge eating disorder (BED),<br />
it is also supported by strong evidence-based literature.<br />
With regard to the efficacy of CBT specifically in BN, in various studies CBT was associated with more improvements in bulimic and<br />
depressive symptoms of patients than symtoms of control patients in waiting-list and any other psychotherapy cases. In terms of general<br />
psychiatric symptoms, studies have not shown any difference between CBT and any other psychotherapy.<br />
Other psychotherapy choices have included interpersonal psychotherapy (IPT), dialectical behavior therapy, supportive and psychodynamic<br />
psychotherapy, and certain self-help approaches. Thus, in clinical practice there have been a number of evidence-supported treatments<br />
for BN patients.<br />
IPT is a psychological treatment for BN that has demonstrated long-term outcomes that are comparable to those for CBT. Currently,<br />
all controlled studies of IPT for BN have been comparison studies with CBT. Although there have been only few controlled trials of<br />
psychodynamic treatment of eating disorders, these reports yielded important findings in this field. Standard dialectical behavior therapy<br />
(DBT) has been adapted to address a variety of problematic behaviors associated with emotion dysregulation in bulimia nervosa and<br />
also DBT may be used in BN patients with comorbid borderline personality disorder. Beside these, the knowledge in the field of self-help<br />
treatments continues to develope.<br />
Key words: Bulimia nervosa, psychotherapy<br />
Bulletin of Clinical Psychopharmacology 2011;21(Suppl. 2):S94-5<br />
[PS-21]<br />
Symposium Title: Treatment approaches to comorbidities of ADHD<br />
Treatment approaches to psychiatric comorbidities of ADHD in children<br />
Tümer Türkbay<br />
GATA, Department of Child and Adolescent Psychiatry, Ankara, Turkey<br />
E-mail: tumerturkbay@yahoo.com;tturkbay@gata.edu.tr<br />
Attention-deficit hyperactivity disorder (ADHD) is highly comorbid with other psychiatric disorders. Each of the comorbid disorders<br />
modifies the overall clinical presentation and treatment response. Sometimes there can be more complex situations. For example,<br />
depressed children demonstrate diminished concentration and irritability and it may be difficult to differentiate from the cardinal<br />
symptoms of ADHD. Children with ADHD and comorbid disorders have poorer prognoses than those with ADHD alone.<br />
Both stimulant medications and atomoxetine markedly reduce symptoms of comorbid oppositional defiant disorder, which often requires<br />
adjunctive parent training and behavior management. Severely explosive anger may require the use of atypical antipsychotics. In conduct<br />
disorder, stimulant medications and atomoxetine also reduce aggressive behavior and antisocial acts. Atypical psychotics or mood<br />
stabilizers may be used for highly aggressive-explosive cases.<br />
The majority of children with comorbid ADHD/depression can be managed with a psycho stimulant. However, initial treatment with<br />
antidepressant drugs should be saved for treating children with more severe depression. Stimulants can exacerbate symptoms of anxiety<br />
disorders. Atomoxetine, SSRIs and behavioral therapies reduce anxiety symptoms.<br />
If tic disorders are mild or episodic, they usually require no treatment. Most ADHD/tic disorder patients will not demonstrate an<br />
exacerbation of their tics with stimulants. Nevertheless, if tics worsen with stimulant use, an antipsychotic or alpha agonist should be<br />
added to the psychostimulant.<br />
Key words: Attention deficit hyperactivity disorder, comorbidity, management<br />
Bulletin of Clinical Psychopharmacology 2011;21(Suppl. 2):S95<br />
S95